Compare Adaptive Biotechnologies Corp (ADPT) vs Humana Inc (HUM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Humana Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Humana Inc trades at $402.15 (market cap $47.38B). The key difference: Humana Inc is far larger — about 14.2× Adaptive Biotechnologies Corp's market cap, and Humana Inc pays a 0.9% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HUM | |
|---|---|---|
Market Cap | $3.33B | $47.38B |
Sector | Health | Health |
52-Week High | $22.37 | $409.42 |
52-Week Low | $10.24 | $163.67 |
Enterprise Value | $3.19B | $56.42B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Humana (HUM) trades at $394.62, down 0.54% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. Revenue growth is strong, reaching $129.66B in 2025, though net income margin has compressed to 0.82%. Recent news highlights expansion through Medicaid contracts and divestitures, alongside legal scrutiny over healthcare costs. The stock shows resilience with consistent earnings beats but faces profitability pressures.
Outlook is mixed: bullish technicals and revenue growth support upside, but margin erosion and legal risks pose challenges. Analysts are cautious with a consensus hold rating and price target of $315, below the current price. Investors should weigh solid fundamentals against regulatory and competitive headwinds for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
